JP2019530431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530431A5 JP2019530431A5 JP2019504106A JP2019504106A JP2019530431A5 JP 2019530431 A5 JP2019530431 A5 JP 2019530431A5 JP 2019504106 A JP2019504106 A JP 2019504106A JP 2019504106 A JP2019504106 A JP 2019504106A JP 2019530431 A5 JP2019530431 A5 JP 2019530431A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence
- car
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 51
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100032530 Glypican-3 Human genes 0.000 claims description 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366731P | 2016-07-26 | 2016-07-26 | |
| US201662366729P | 2016-07-26 | 2016-07-26 | |
| US62/366,729 | 2016-07-26 | ||
| US62/366,731 | 2016-07-26 | ||
| PCT/EP2017/068654 WO2018019772A1 (en) | 2016-07-26 | 2017-07-24 | Chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530431A JP2019530431A (ja) | 2019-10-24 |
| JP2019530431A5 true JP2019530431A5 (enExample) | 2020-09-03 |
Family
ID=59569287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504106A Withdrawn JP2019530431A (ja) | 2016-07-26 | 2017-07-24 | キメラ抗原受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190262397A1 (enExample) |
| EP (1) | EP3490589A1 (enExample) |
| JP (1) | JP2019530431A (enExample) |
| KR (1) | KR20190038567A (enExample) |
| CN (1) | CN110035768A (enExample) |
| AU (1) | AU2017301826A1 (enExample) |
| CA (1) | CA3031846A1 (enExample) |
| SG (1) | SG11201900634VA (enExample) |
| TW (1) | TW201806969A (enExample) |
| WO (1) | WO2018019772A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121731464A (zh) * | 2016-04-22 | 2026-03-27 | 克莱格医学有限公司 | 用于细胞免疫疗法的组合物和方法 |
| JP7196094B2 (ja) * | 2017-03-29 | 2022-12-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子 |
| CN108913709A (zh) * | 2018-06-26 | 2018-11-30 | 山东兴瑞生物科技有限公司 | 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法 |
| CN112469829B (zh) * | 2018-07-17 | 2023-07-07 | 诺伊尔免疫生物科技株式会社 | 包含抗gpc3单链抗体的car |
| US11691976B2 (en) * | 2018-08-23 | 2023-07-04 | Promega Corporation | Coelenterazine analogues |
| MX2021003744A (es) * | 2018-10-01 | 2021-06-23 | Adicet Bio Inc | Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos. |
| CN112300288B (zh) * | 2019-07-29 | 2022-08-02 | 济南赛尔生物科技股份有限公司 | 一种cik细胞的嵌合抗原受体car及其应用 |
| CN114901294A (zh) * | 2019-09-10 | 2022-08-12 | 赛通免疫治疗公司 | 双特异性抗体car细胞免疫疗法 |
| IL291924A (en) * | 2019-10-07 | 2022-06-01 | Fate Therapeutics Inc | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| CN110790842B (zh) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用 |
| EP4076503A4 (en) * | 2019-12-20 | 2024-04-03 | MedImmune, LLC | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN 3 |
| CN113087806B (zh) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | 靶向多种肿瘤的新型car-t细胞及其制备和方法 |
| CN115461449A (zh) * | 2020-03-18 | 2022-12-09 | 优特力克斯有限公司 | 分泌il-18的gpc3 car-t细胞及其制备和使用方法 |
| WO2021186397A1 (en) * | 2020-03-18 | 2021-09-23 | Eutilex Co., Ltd. | Gpc3 car-t cell compositions and methods of making and using the same |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| WO2023024084A1 (zh) * | 2021-08-27 | 2023-03-02 | 原启生物科技(上海)有限责任公司 | 一种嵌合抗原受体及其用途 |
| CN122029205A (zh) * | 2023-09-19 | 2026-05-12 | 北京沙砾生物医药股份有限公司 | 一种融合蛋白及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629013B1 (en) | 2003-05-31 | 2018-01-24 | Amgen Research (Munich) GmbH | Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| US20050180979A1 (en) | 2004-02-13 | 2005-08-18 | Micromet Ag | Anti-EpCAM immunoglobulins |
| CA2544692C (en) | 2004-07-09 | 2014-04-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| AU2005297772B2 (en) | 2004-10-26 | 2011-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| ES2367675T3 (es) | 2007-04-04 | 2011-11-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anticuerpo anti-epcam y usos del mismo. |
| DK2178921T3 (en) | 2007-07-17 | 2016-04-04 | Squibb & Sons Llc | Monoclonal antibodies to glypican 3 |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20110165161A1 (en) | 2009-12-23 | 2011-07-07 | Shih-Yao Lin | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
| EP2614077B1 (en) | 2010-09-08 | 2016-08-17 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| WO2012145469A1 (en) | 2011-04-19 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| WO2012153186A2 (en) | 2011-05-06 | 2012-11-15 | Kalgene Pharmaceuticals Inc. | Monoclonal antibodies to epcam-icd and methods for detecting epithelial cancer cells |
| US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| CN104168916B (zh) | 2012-03-02 | 2017-07-04 | 中央研究院 | 抗上皮细胞黏着分子(EpCAM)抗体及其使用方法 |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US9409994B2 (en) | 2012-06-01 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| CN107460201A (zh) | 2013-05-08 | 2017-12-12 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| BR112016007232A2 (en) | 2013-10-02 | 2018-01-23 | Viventia Bio Inc. | anti-epcam antibodies and methods of use |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| US20170081411A1 (en) * | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| US9777061B2 (en) * | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| US20170209492A1 (en) * | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| SG11201700770PA (en) * | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| EP3858991A1 (en) | 2014-09-26 | 2021-08-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| US11459390B2 (en) * | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
-
2017
- 2017-07-24 AU AU2017301826A patent/AU2017301826A1/en not_active Abandoned
- 2017-07-24 CA CA3031846A patent/CA3031846A1/en not_active Abandoned
- 2017-07-24 EP EP17749637.9A patent/EP3490589A1/en not_active Withdrawn
- 2017-07-24 KR KR1020197004478A patent/KR20190038567A/ko not_active Ceased
- 2017-07-24 SG SG11201900634VA patent/SG11201900634VA/en unknown
- 2017-07-24 JP JP2019504106A patent/JP2019530431A/ja not_active Withdrawn
- 2017-07-24 CN CN201780059507.6A patent/CN110035768A/zh active Pending
- 2017-07-24 WO PCT/EP2017/068654 patent/WO2018019772A1/en not_active Ceased
- 2017-07-24 US US16/320,055 patent/US20190262397A1/en not_active Abandoned
- 2017-07-25 TW TW106124862A patent/TW201806969A/zh unknown